Day 1 | Wednesday, September 29

Day 2 | Thursday, September 30

Moving Treatments Towards Target Populations

• Identify new commercial precision medicine opportunities to innovate your pipeline and de-risk CDx investment

Leveraging Data & Trends in Biomarkers & Diagnostics Collaboration and Data Sharing

• Maximize the utility of data and identify diagnostic advances to increase your clinical suspicion

Moving Biomarkers Towards the Clinic Clinical Biomarker & Assay Development Drug-Dx Co-Development
 

 

Moving the Needle in Immuno-Oncology

Overcome disease heterogeneity,
toxicity risk and microenvironment cues

 

Early Biomarker Decision Making
for Time-Efficient Clinical
Planning

 

Exploring Pathways for Drug-Dx Co-Development
MUST SEE SESSION:
Reliable & Accurate TMB Measurements by NGS Panels 
 

 

Build prognostic and predictive biomarkers in earlier studies to fast track CDx planning and streamline regulatory submission for US and EU approval       

Establish seamless cross-functional communication across biopharma stakeholders to achieve launch
readiness

 

MUST SEE SESSION:
CDx Pathways for Gene Therapy and Rare Disease

Break
Showcase Your Scientific Poster: Share you cutting edge research and learn how others are tackling similar challenges to you
Break
 

Novel Preclinical Models for
Biomarker Identification

Utilize predictively valid pre-clinical
models in Alzheimer’s & NSCLC to better recapitulate disease biology

Explore insights across indications with:

 

 

 

 

Defining Patient Populations for
Faster, More Conclusive Trial Completion

MUST SEE SESSION:
Use of NY-ESO-1 T-Cell Therapy in Patients with Mixed Round Cell Liposarcoma in NYESO-1 Positive Tumors

 

 

 

Navigating the Fast Growing
CDx Market

Delve into the global footprint of today’s testing paradigm to enable strategic cost effective Drug-Dx development

 

MUST SEE SESSION:
Finding a Compatible
Partner in the CDx Space

Break
Evidence Enabling Biomarker Strategy Decision Making
Apply learnings from successful end-to-end CDx
development to give your strategy the competitive edge
MUST SEE SESSION:
Jemperli Approval Case Study
Break
Moving Biomarkers Towards the Clinic Clinical Biomarker & Assay Development Drug-Dx Co-Development
 

 

 

Broaden the Scope of Validated
Biomarkers

Leverage new technologies to drive biomarker discovery

 

Overcome Complexities in Biomarker Trial Design

Effectively evaluate therapies clinically
with streamlined combination trial
execution and advanced genomic
analysis techniques

Discover Diagnostic Innovations in Emerging Markets
MUST SEE SESSION:
The UK Biobank Pharma Proteomics Project
 

 

HEAR UPDATES FROM:

Gristone Bio’s Neoantigen
Immunotherapy Pipeline Pieris Pharmaceutical’s first-in-class bispecific fusion protein

Set up an impactful Rx-Dx strategy in unchartered waters

Comprehensively assess a market landscape for a precise picture of the
competitive landscape

 

Break
New Interactive IVDR Session: Plan ahead for incoming European regulatory framework alongside your global peers
Break
 

Achieve Clinical ‘Buy In’ to Translate New Biomarkers to the Clinic

Overcoming sample limitations with biospecimen databases

Enter the clinic with a pre-clinical data package enabling objective clinical endpoints

Liquid Biopsy paving the way for Earlier Intervention

Discuss the latest thinking on ctDNA
for MRD monitoring to develop novel
treatment options

Overcome sensitivity and specificity challenges with industry assay standardization

 

Ensuring Testing Access in Routine Practice

MUST SEE SESSION:
VITRAKVI Real World Data &
Strategies Broadening Assay
Adoption

Break
Apply AI & Advanced Analytics to Progress Medicines
Integrate big data and AI systems into workflows to accelerate
diagnostic and prognostic biomarker development

Break